Oragenics, Inc.

As of August 12, 2016, Oragenics, Inc. is considered overvalued due to its negative financial metrics, including a non-applicable P/E ratio, a Price to Book Value of 3.06, an EV to EBITDA of -0.22, and a severely low ROE of -1033.41%, alongside significant underperformance compared to the S&P 500.

As of June 10, 2025, Oragenics, Inc. has shifted to a mildly bearish trend due to bearish daily moving averages and indicators, despite some mildly bullish signals from weekly and monthly MACD, with overall performance lagging behind the S&P 500.

As of March 2022, the management team of Oragenics, Inc. includes Dr. Frederick Telling (Independent Chairman), Dr. Alan Joslyn (President and CEO), Ms. Kim Murphy, Dr. Alan Dunton, Mr. Robert Koski, and Mr. Charles Pope, all serving as directors. They are responsible for guiding the company's strategic direction and operations.

Oragenics, Inc. is a micro-cap healthcare company focused on developing treatments for oral mucositis and novel antibiotics. As of March 2025, it reported a net profit loss of $2 million and has a market cap of $3.13 million.

As of Jun 18, Oragenics, Inc. has a market capitalization of 3.13 million, with net sales of 0.00 million and a net profit of -10.34 million over the latest four quarters. The company reported shareholder's funds of -0.21 million and total assets of 1.47 million as of Dec 24.